Loading…
Employees: 214
Size Philogen (PHIL.MI) is an Italy Health Care company (Pharmaceuticals: Major) with a market value of $694M, the 96th largest of 123 Italy companies the cockpit tracks. Shares closed at €21.15 on 6 Nov 2026.
Performance Over six months the shares fell 6.8%, against -5.6% for the median peer and +3.1% for the Italy market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 294.9% over the last twelve months (peer median +10.1%); the operating margin is 78.8% (peer median 10.7%).
Valuation It trades at 32.5× forward earnings against a peer median of 15.2× (4th most expensive of 10).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €311M | €314M | €74.0M | €23.1M | €23.7M |
| Revenue growth | — | +325% | +220% | -2% | — |
| Gross profit | €263M | €272M | €39.5M | -€6.36M | €914,000 |
| EBITDA | €250M | €256M | €38.0M | -€7.19M | -€561,000 |
| Net income | €225M | €230M | €45.3M | -€6.16M | -€5.38M |
| Free cash flow | €268M | €268M | €40.4M | -€8.80M | -€8.58M |
| Capital expenditure | €2.20M | €3.63M | €2.41M | €5.86M | €4.21M |
| Total debt | n/a | €10.9M | €11.5M | €14.9M | €15.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHIL.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.2% | -5.0% | 10th highest of 21 |
| 6-month return | -6.8% | -5.6% | 9th lowest of 21 |
| Distance from 52-week high | -18.6% | -26.1% | 6th highest of 21 |
| Revenue growth (TTM) | +294.9% | +10.1% | highest of 17 |
| Operating margin | 78.8% | 10.7% | highest of 16 |
| Forward P/E | 32.5× | 15.2× | 4th most expensive of 10 |
| EV / EBITDA | 1.2× | 12.7× | cheapest of 7 |
| Net debt / EBITDA | -1.3× | -1.1× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |